Notable Expands Executive Leadership Team with Appointment of Dr. Kevin Lynch as Chief Business Officer

Notable Expands Executive Leadership Team with Appointment of Dr. Kevin Lynch as Chief Business Officer

Industry Dealmaker Joins Notable to Accelerate In-licensing Strategy to Fuel Predictive Precision Platform and Pipeline Foster City, Calif., January 6, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company, announced the appointment of Kevin Lynch, Ph.D., M.B.A, as Chief Business Officer. Dr. Lynch has decades of deal-making experience within pharma, and recently led […]

Prediction of clinical response to venetoclax plus decitabine in AML using a 7-day ex vivo assay
,

Prediction of clinical response to venetoclax plus decitabine in AML using a 7-day ex vivo assay

The combination of venetoclax (VEN) and a hypomethylating agent (HMA) such as decitabine (DEC) is frequently used in acute myeloid leukemia (AML) for patients unfit for standard chemotherapy. However, there is a subset of patients who do not clinically respond to such combination therapies. To identify VEN + HMA non- responders prior to treatment we developed an assay on our automated, high throughput (HTS) ex vivo drug sensitivity platform to predict how a given patient will clinically respond to DEC + VEN within an ongoing, open label, phase II clinical trial (NCT03404193) for patients with newly diagnosed elderly/unfit or relapsed/refractory (R/R) AML.

Ex Vivo Drug Sensitivity Assay Correlates with Clinical Response and Identifies Panobinostat and Bortezomib as a Potential Novel Drug Combination for Pediatric AML
,

Ex Vivo Drug Sensitivity Assay Correlates with Clinical Response and Identifies Panobinostat and Bortezomib as a Potential Novel Drug Combination for Pediatric AML

Pediatric acute myeloid leukemia (AML) is a rare disease with roughly 600 cases diagnosed in the United States each year with minimal improvement in clinical outcomes over the last few decades. Diagnostic pediatric AML samples were assayed using an ex vivo drug sensitivity test to determine the correlation between ex vivo drug response and clinical outcome, and to compare conventional chemotherapy to other drug combinations ex vivo.

Notable Presents Clinical Validation Data from Two Phase 2 Trials in Adult and Pediatric Acute Myelogenous Leukemia at the 63rd American Society of Hematology (ASH) Annual Meeting

Notable Presents Clinical Validation Data from Two Phase 2 Trials in Adult and Pediatric Acute Myelogenous Leukemia at the 63rd American Society of Hematology (ASH) Annual Meeting

Studies demonstrate high correlation between predicted response by Notable’s predictive precision medicines platform and actual clinical response, short-term and at one year Interim analyses of studies with MD Anderson Cancer Center and Texas Children’s Hospital investigators corroborate platform prediction data from Standford University collaboration Foster City, Calif., December 16, 2021 – Notable Labs, Inc. (Notable), […]

Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement

Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platform With The Goal Of Assessing Patient Responsiveness To Fosciclopirox Foster City, Calif. and Kansas City, Mo., December 1, 2021 – Notable Labs, Inc. (Notable), a clinical-stage predictive precision therapeutics company and CicloMed LLC (CicloMed), a developmental-stage pharmaceutical company have initiated a Phase 1B/2A clinical trial of […]

Notable Expands Executive Leadership Team with Appointment of Christopher Whitmore as Chief Financial Officer

Notable Expands Executive Leadership Team with Appointment of Christopher Whitmore as Chief Financial Officer

Foster City, Calif., November 23, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, today announced the appointment of Chris Whitmore as Chief Financial Officer. In this role, Mr. Whitmore will be a key member of the executive leadership team and will lead Notable’s financial strategy, planning […]

Clinical Data on the Notable Predictive Precision Medicines Platform Presented at the 63rd ASH Annual Meeting

Clinical Data on the Notable Predictive Precision Medicines Platform Presented at the 63rd ASH Annual Meeting

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platformto Accelerate Clinical Development and Maximize Patient Outcomes Foster City, Calif., November 22, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company, today announced two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. “These two clinical […]

Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib

Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platform to Accelerate Clinical Trial Timelines and Maximize Patient Outcomes Volasertib is a PLK-1 inhibitor with therapeutic potential across a range of tumor types Foster City, Calif., November 11, 2021 – Notable Labs, Inc. (Notable), a pioneer and developer of predictive precision medicines, has obtained worldwide rights […]

Ex vivo drug sensitivity assay correlates with clinical response in pediatric AML
,

Ex vivo drug sensitivity assay correlates with clinical response in pediatric AML

Listen to the exciting results from Notable's collaboration with Texas Children's Cancer Center highlighting response prediction in a pediatric acute myeloid leukemia (AML) study that was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The data was presented by Dr. Alexandra Stevens from Texas Children's and demonstrates the correlation of functional drug sensitivity screening using Notable’s predictive technology platform with the clinical outcomes of pediatric patients.

Correlation of ex vivo drug sensitivity with clinical response in pediatric AML
,

Correlation of ex vivo drug sensitivity with clinical response in pediatric AML

Pediatric acute myeloid leukemia (AML) is a rare disease with roughly 500 cases diagnosed in the United States each year and has had minimal improvement in clinical outcomes over recent decades. Novel treatment development to improve outcomes may be enhanced with an accompanying test for predicting treatment response.

Notable Labs to Attend BIO Digital 2021 Highlighting Predictive Technology Platform for Oncology

Notable Labs to Attend BIO Digital 2021 Highlighting Predictive Technology Platform for Oncology

FOSTER CITY, CA – June 10, 2021 — Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced that it will be attending BIO Digital 2021, a key international biotech partnering event held virtually on June 14-18. During the conference Notable […]

Notable Labs to Present at ASCO 2021 Highlighting Prediction Technology Platform

Notable Labs to Present at ASCO 2021 Highlighting Prediction Technology Platform

FOSTER CITY, CA – June 4, 2021 — Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced top-line results from its clinical response prediction technology platform in a pediatric acute myeloid leukemia (AML) study to be presented at the 2021 […]

Acute Myeloid Leukemia: Did You Know?

Acute Myeloid Leukemia: Did You Know?

April 21st, 2021 is Acute Myeloid Leukemia (AML) World Awareness Day. On this day, we want to help raise awareness of this rare, aggressive form of cancer that happens in the blood and bone marrow. It is characterized by an excess of immature white blood cells and low quality red blood cells. It is the […]

Notable Names Dr. Thomas A. Bock as CEO

Notable Names Dr. Thomas A. Bock as CEO

FOSTER CITY, CA – March 31, 2021 – Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced the appointment of Thomas A. Bock, MD, MBA, as Chief Executive Officer.

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
,

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after <6 months (early relapse [ER]).

Analysis of Heme/Onc Drug Sensitivity Data
,

Analysis of Heme/Onc Drug Sensitivity Data

Explore how integrative multi-omics drug sensitivity data can improve your drug development.

Notable Labs to Present Analysis of Hematologic Oncology Drug Sensitivity Data

Notable Labs to Present Analysis of Hematologic Oncology Drug Sensitivity Data

FOSTER CITY, CA – January 26, 2021 – Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced that it is hosting a live webinar on February 9th to unveil their integrative data platform.

Notable Labs to present at Biotech Showcase™ Digital 2021

Notable Labs to present at Biotech Showcase™ Digital 2021

FOSTER CITY, CA – January 8, 2021 – Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced that it is participating in Biotech Showcase™ 2021 and will be presenting the strategic plan for long-term growth.

Emerging Technical and Precision Medicine Approaches for Higher Risk Myelodysplastic Syndromes

Emerging Technical and Precision Medicine Approaches for Higher Risk Myelodysplastic Syndromes

Novel precision medicine approaches such as Notable Labs’ ex vivo DSS identify rational drugs and drug combinations and predict clinical therapeutic responses

Getting the right cancer drugs to the right patients relies on the accurate prediction of clinical response to an ever-increasing array of cancer therapies.

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms
,

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity.

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion- positive AML Defines Novel Therapeutic Options – A COG and TARGET Pediatric  AML Study
,

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion- positive AML Defines Novel Therapeutic Options – A COG and TARGET Pediatric AML Study

A cryptic inv(16)(p13.3q24.3) encoding the CBFA2T3-GLIS2 fusion is associated with poor outcome in infants with acute megakaryocytic leukemia. We aimed to broaden our understanding of the pathogenesis of this fusion through transcriptome profiling.

September is Blood Cancer Awareness Month

September is Blood Cancer Awareness Month

Living with Adult Acute Lymphoblastic Leukemia September is Blood Cancer Awareness Month. The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer and has helped advance 54 of the 64 blood cancer treatment options approved by the U.S. Food and Drug Administration since 2017. This month the LLS announced it […]

Emerging Treatment Approaches of High-Risk Myelodysplastic Syndrome
,

Emerging Treatment Approaches of High-Risk Myelodysplastic Syndrome

The Stanford University Cancer Center and the MDS Foundation are proud to bring you this complimentary webinar presented by Stanford’s Dr. Michael Spinner, post-doctoral medical fellow, oncology, and moderated by the MDS Foundation’s Sandra Kurtin, Ph.D., ANP-C, AOCN.

How We Capture Mechanism of Action in the Notable Platform

How We Capture Mechanism of Action in the Notable Platform

Notable has developed a versatile platform for testing a wide variety of drugs in patient ex vivo clinical samples, with a high-throughput flow cytometry readout that incorporates diverse phenotypes, including measures of apoptosis, proliferation, differentiation, and stemness, as well as immunotherapy targets.

Getting the right cancer drugs to the right patients relies on the accurate prediction of clinical response to an ever-increasing array of cancer therapies.

Notable’s Mission to Move Beyond a  “One-Size-Fits-All” <em>Ex Vivo</em> Drug Sensitivity Test

Notable’s Mission to Move Beyond a “One-Size-Fits-All” Ex Vivo Drug Sensitivity Test

Figure 1: Heatmap showing responses to 31 drugs or drug combinations (rows) in 37 blood cancer patient samples (columns). Each colored box represents the level of ex vivo drug sensitivity, with red indicating the highest level of sensitivity and blue the lowest. Getting the right cancer drugs to the right patients relies on the accurate […]

Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples
,

Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples

Prognoses for acute promyelocytic leukemia (APL) patients improved drastically upon the introduction of differentiation therapy with all-trans-retinoic acid (ATRA) in combination with conventional chemotherapy. Unfortunately, this therapeutic approach has not translated to other genetic subtypes of acute myeloid leukemia...

PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells
,

PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells

To identify cancer cell types that are sensitive to PTC299, a panel of 240 tumor cell lines was tested against which the concentration of compound required to reduce cell viability by 50% (CC50) was determined. Overall, the viability of 18% of cells from solid tumor(34/184) and ~57% of cells from hematologic malignancies (32/56) was reduced...

Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression
,

Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression

The barcodes were then used to reassemble the genetic profiles of cells from next-generation sequencing data. We applied this approach to sequential clinical MDS samples, genotyping the most clinically relevant loci across more than 15,000 individual cells. Additionally, to study effects of subclonal mutations on drug sensitivity, ex vivo functional...

Recurrent drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling
,

Recurrent drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling

Myelodysplastic syndromes (MDS) are a collection of clonal diseases of dysfunctional hematopoietic stem cells, characterized by ineffective hematopoiesis, cytopenias, and dysplasia. Limited conventional treatment options exist for these patients, with hypomethylating agents remaining the standard of care for higher-risk MDS patients.

Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy
,

Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy

The clinical heterogeneity of the myelodysplastic syndromes (MDSs) relates to the recently discerned panoply of molecular abnormalities extant within this disease spectrum. Despite increasing recognition of these biologic abnormalities, very limited therapeutic options exist to exploit our increasing understanding of the molecular pathophysiology of MDS.

Ex Vivo Drug Sensitivity Profiling In Myelodysplastic Syndrome (MDS) Patients Defines Novel Drug Sensitivity Patterns For Predicting Clinical Therapeutic Outcomes
,

Ex Vivo Drug Sensitivity Profiling In Myelodysplastic Syndrome (MDS) Patients Defines Novel Drug Sensitivity Patterns For Predicting Clinical Therapeutic Outcomes

We performed drug sensitivity profiling on 60 patient samples in both newly diagnosed and treatment-refractory myeloid neoplasms (46 MDS, 4 CMML, 10 AML). Fresh bone marrow aspirates and/or peripheral blood specimens were RBC-lysed and re-suspended in serum-free media with cytokines.

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents
,

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

We performed a prospective feasibility study in 21 patients with HMA-refractory MDS enrolled at Stanford University from April 2018 through March 2019. All patients had a baseline bone marrow (BM) biopsy with BM aspirate and peripheral blood (PB) samples sent for mutation testing (596-gene panel, Tempus, Chicago, IL) and ex vivo DSS (Notable Labs, Foster City, CA).

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options – a COG and Target Pediatric AML Study
,

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options – a COG and Target Pediatric AML Study

A cryptic inv(16)(p13.3q24.3) encoding the CBFA2T3-GLIS2 fusion is associated with poor outcome in infants with acute megakaryocytic leukemia. We aimed to broaden our understanding of the pathogenesis of this fusion through transcriptome profiling. Experimental Design: Available RNA from children and young adults with de novo AML (N=1,049) underwent transcriptome sequencing (mRNA and miRNA).

SY-1425, A Potent and Selective RARA Agonist, Reprograms AML Cells for Differentiation Along Distinct Lineages Uncovering PD Markers for Clinical Studies
,

SY-1425, A Potent and Selective RARA Agonist, Reprograms AML Cells for Differentiation Along Distinct Lineages Uncovering PD Markers for Clinical Studies

A subgroup of the patient samples was defined by an SE driving RARA, which co-occurred with SEs driving FOS and JUNB, or IRF8. FOS and JUNB form the AP-1 heterodimeric TF known to promote an immature cell state and the interferon regulatory factor 8 (IRF8) pathway has been implicated in AML pathogenesis.

Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients
,

Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients

SY-1425 (tamibarotene) is an oral, potent and selective synthetic RARα agonist previously approved for the treatment of relapsed/refractory acute promyelocytic leukemia (APL) in Japan. Given preclinical evidence of SY-1425 sensitive AML cell lines and patient samples with RARA pathway activation defined by elevated RARA or IRF8, SY-1425 is being...

RARA Pathway Activation Biomarkers in Study SY-1425-201 Define a New Subset of AML and MDS Patients and Correlate with Myeloid Differentiation Following Ex Vivo SY 1425 Treatment
,

RARA Pathway Activation Biomarkers in Study SY-1425-201 Define a New Subset of AML and MDS Patients and Correlate with Myeloid Differentiation Following Ex Vivo SY 1425 Treatment

We developed an epigenetic approach to profile the gene regulatory landscape of primary AML/MDS patient samples. A novel patient subset defined by RARA pathway activation was identified by super-enhancers (SEs) at the RARA and IRF8 gene loci.

Early Results from a Biomarker-Directed Phase 2 Trial of SY-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following SY-1425 Treatment
,

Early Results from a Biomarker-Directed Phase 2 Trial of SY-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following SY-1425 Treatment

Bone marrow biopsies (H&E) at 40x from screening (A) and C3D1 (B). Bone marrow aspirate (WG stain) at 100x from screening (C) and C3D1 (D). (A) Blasts (black arrows) occur in many small groups. Maturing myeloid cells (yellow arrows), erythroid precursors (red arrows) and megakaryocytes (blue arrows) are also present.

Successful Treatment with Bortezomib, Panobinostat, and Dexamethasone of Acute Myeloid Leukemia (AML) in 2nd Relapse After Allogeneic Stem Cell Transplantation (SCT): Therapy Selected Based Upon Results of a Personalized Flow Cytometric Screen for Drug
,

Successful Treatment with Bortezomib, Panobinostat, and Dexamethasone of Acute Myeloid Leukemia (AML) in 2nd Relapse After Allogeneic Stem Cell Transplantation (SCT): Therapy Selected Based Upon Results of a Personalized Flow Cytometric Screen for Drug

Notable Labs uses a flow cytometric-based assay to test a panel of FDA-approved chemotherapy and targeted agents—singly and in combinations using a custom robotic platform—to determine anti-cancer effect against individual patient’s tumor cells.

Differential drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling
,

Differential drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling

Blood or bone marrow samples were red blood cell lysed upon arrival, counted and resuspended at the appropriate concentration in proprietary serum free media with cytokines. The samples were then plated in 384 well microtiter plates and treated with drugs in triplicate (for each staining panel) using an Echo acoustic dispenser.

Ex Vivo Drug Response Profiling Defines Novel Drug Sensitivity Patterns for Predicting Clincal Therapeutic Responses in Myeloid Neoplasms
,

Ex Vivo Drug Response Profiling Defines Novel Drug Sensitivity Patterns for Predicting Clincal Therapeutic Responses in Myeloid Neoplasms

Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) are clonal myeloid neoplasms for which limited conventional treatment options exist in the relapsed / refractory setting, especially for older patients.

Frequently Asked Questions (FAQ)

Frequently Asked Questions (FAQ)

Notable Labs is redefining cancer treatment by taking a functional approach to precision oncology in blood cancers. This cutting-edge science will facilitate drug development and enable pharmaceutical companies to get new therapies to patients faster.

Notable has developed a custom precision medicine platform that blends high-throughput flow cytometry with advanced automation and a streamlined analysis pipeline. This platform has been optimized to analyze drug sensitivity across many drug classes in primary patient...

Profiling of Rigosertib Identifies Distinct Classes of Responders in Myelodysplastic Syndrome

Profiling of Rigosertib Identifies Distinct Classes of Responders in Myelodysplastic Syndrome

Myelodysplastic syndromes (MDS) are clonal neoplasms with dysfunctional hematopoietic stem cells characterized by ineffective hematopoiesis, cytopenias, and have a substantial risk of transformation to AML.

Myelodysplastic syndromes (MDS) are clonal neoplasms with dysfunctional hematopoietic stem cells characterized by ineffective hematopoiesis, cytopenias, and have a substantial risk of transformation to AML. The hypomethylating agents (HMAs) azacytidine and decitabine are the standard...

Notable’s The ANSWer Study

Notable’s The ANSWer Study

Notable’s The ANSWer Study: An Observational Clinical Trial for Patients with Blood Cancer by Susanna Wen MsM (Master of Medicine), Ph.D Notable’s first self-sponsored clinical trial to validate cancer patient matching on its automated high-throughput scientific technology platform At Notable, we are aiming to redefine cancer treatment with the development of a functional precision medicine […]

What is precision medicine?

What is precision medicine?

In the world of oncology, precision medicine has been synonymous with genomics. Once genetic abnormalities are identified in a patient through cytogenetics and sequencing, an appropriate therapy can be identified that exploits this abnormality thought to be driving cancer growth. One of the best success stories… oncology precision medicine has been the genetic.